Pharmacological Management of Type 2 Diabetes Complications

Curr Vasc Pharmacol. 2020;18(2):101-103. doi: 10.2174/157016111802200101155519.

Authors

Michael Doumas^{1

2}, Konstantinos Imprialos¹, Konstantinos Stavropoulos¹, Vasilios G Athyros¹

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
² George Washington University, Washington, DC, United States.

PMID: 32013814
DOI: 10.2174/157016111802200101155519

No abstract available

Keywords: Dyslipidaemia; cardiovascular risk factors; comorbidities; expert consensus; lipid management..

Publication types

Editorial
Introductory Journal Article

MeSH terms

Animals
Diabetes Complications / diagnosis
Diabetes Complications / drug therapy*
Diabetes Complications / epidemiology
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use*
Treatment Outcome

Substances

Hypoglycemic Agents